Statin induced myopathy treatments
[DOCX File]Product Information for Tarceva
https://info.5y1.org/statin-induced-myopathy-treatments_1_dd2d95.html
Side effect such as statin-induced myopathy (muscle damage) and rhabdomyolysis (muscle destruction) are a major concern, but the potential benefit of perioperative statin therapy appear to outweigh the risk of potential hazard. Therapy should be initiated a few days before surgery in combination with dose adjustment for tight heart rate control.
[DOC File]WATER DEPRIVATION TEST AND DESMOPRESSIN TEST IN …
https://info.5y1.org/statin-induced-myopathy-treatments_1_7a7f13.html
The combination of TARCEVA and a statin may increase the potential for statin-induced myopathy, including rhabdomyolysis, which was observed rarely. In a Phase Ib study, there were no significant effects of gemcitabine on the pharmacokinetics of TARCEVA nor were there significant effects of TARCEVA on the pharmacokinetics of gemcitabine.
[DOCX File]Oregon
https://info.5y1.org/statin-induced-myopathy-treatments_1_279a8d.html
Monitor INR prior to commencing a statin, fibrate or Omacor and around the time of dose adjustments. If prescribing drugs which may also induce or inhibit cytochrome P450 3A4 increased INR monitoring or statin withdrawal is needed. References. 1 Statin induced myopathy (Clinical Review). BMJ 2008; 337: 1159-1162
[DOCX File]Title: Statin Induced Autoimmune Myopathy
https://info.5y1.org/statin-induced-myopathy-treatments_1_a26526.html
The authors of the same systematic review also searched MEDLINE (1966-July 2000) and identified 29 published cases of statin-fibrate rhabdomyolysis or myopathy. Of those 29 cases reports, there were no case reports of severe myopathy or rhabdomyolysis in patients receiving pravastatin or fluvastatin combined with a fibrate.
[DOC File]STATIN-FIBRATE REPORT: Focus on Safety
https://info.5y1.org/statin-induced-myopathy-treatments_1_b26651.html
The patient has the features of a statin-induced immune-mediated necrotizing myopathy (IMNM), recently described as being associated with the anti-HMGCR antibody. First-line immunotherapy with glucocorticoids is appropriate while further investigations are undertaken, although many cases of IMNM ultimately require more aggressive immunotherapy.
[DOCX File]University of Manchester
https://info.5y1.org/statin-induced-myopathy-treatments_1_985d18.html
, proof of concept study on SLCO1B1 genetic variants on prediction of statin myelopathy SLCO1B1 c.521T>C single-nucleotide polymorphism to be a significant risk factor (P = 0.009), with an odds ratio (OR) per variant allele of 2.06 (1.32-3.15) for all myopathy and 4.09 (2.06-8.16) for severe myopathy (CPK > 10x ULN, and/or rhabdomyolysis; n = 23).
Statin-induced myopathies.
Statin-induced autoimmune myositis remains a rare (and likely new) subset of the statin-induced myopathy spectrum. As such, presentation, response to treatment and long-term prognosis remain incompletely defined and the evidence base for best- practice treatment is lacking.
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.